Page 91 - Read Online
P. 91

difumarate, (1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-  ACKNOWLEDGMENTS
           1H-1,4-diazepin-1-yl)-benzimidazole difumarate;
           Kowa, Tokyo, Japan). The facilitation of these     We would like to thank Ms. Teresa Ruggle for her
           inhibitors proved mast cells’ contribution to IEL and   assistance with the preparation of the figure.
           media degeneration as both of these processes were
           suppressed. [17]  Ultimately, the facilitation of these   REFERENCES
           inhibitors reduced the size of the induced aneurysms   1.   Juvela S, Poussa K, Lehto H, Porras M. Natural history of unruptured
           and the thinning of the vessel’s media layer. Inhibitors   intracranial aneurysms: a long‑term follow‑up study.  Stroke
           of mast cell degranulation have shown to be useful in   2013;44:2414‑21.
           the treatment of other inflammatory processes such as   2.   Steiner T, Juvela S, Unterberg A, Jung C, Forsting M, Rinkel G;
                                                                  European Stroke Organization. European Stroke Organization
           allergies. [17]  As a result, the authors believe mast cell   guidelines for the management of intracranial aneurysms and
           inhibitors may prove to be a practical and safe future   subarachnoid haemorrhage. Cerebrovasc Dis 2013;35:93‑112.
           anti-inflammatory treatment for IAs. [17]          3.   Juvela S. Prevalence of and risk factors for intracranial aneurysms.
                                                                  Lancet Neurol 2011;10:595‑7.
                                                              4.   Korja M, Lehto H, Juvela S. Response to letter regarding article,
           TNF-α-TNFR1 cascade inhibition is a strategy that has   “lifelong rupture risk of intracranial aneurysms depends on risk
           been recently explored by Aoki et al. [25]  Anti-TNF-α   factors: a prospective finnish cohort study”. Stroke 2014;45:e211.
           antibody or soluble TNF receptor has been successfully   5.   Chalouhi N, Ali MS, Jabbour PM, Tjoumakaris SI, Gonzalez LF,
                                                                  Rosenwasser RH, Koch WJ, Dumont AS. Biology of intracranial
           used in the treatment of an inflammatory disease, such   aneurysms: role of inflammation.  J  Cereb Blood  Flow Metab
           as rheumatoid arthritis.  The authors note that the use   2012;32:1659‑76.
                               [25]
           of these inhibitors in the treatment of aneurysms would   6.   Hudson JS, Hoyne DS, Hasan DM. Inflammation and human
           be likely efficacious; however, the expense of these drugs   cerebral aneurysms: current and future treatment prospects. Future
                                                                  Neurol 2013:8.
           makes an alternative inhibitor of the TNF-α-TNFR1   7.   Chalouhi N, Hoh BL, Hasan D. Review of cerebral aneurysm
           signaling cascade desirable. [25]  In addition, increased   formation, growth, and rupture. Stroke 2013;44:3613‑22.
           levels of TNF-α in unruptured and ruptured IAs in an   8.   Tronc F, Mallat Z, Lehoux S, Wassef M, Esposito B, Tedgui A.
                                                                  Role of matrix metalloproteinases in blood flow‑induced arterial
           in vivo model were reconfirmed by Starke et al.  This   enlargement: interaction with NO. Arterioscler Thromb Vasc Biol
                                                    [62]
           follow-up study focused on the therapeutic strategy of   2000;20:E120‑6.
           the TNF-α-TNFR1 signaling cascade by analyzing TNF-α   9.   Killer‑Oberpfalzer M, Aichholzer M, Weis S, Richling B, Jones R,
           knockout mice and mice administered an inhibitor of    Virmani R, Cruise GM. Histological analysis of clipped human
                                                                  intracranial aneurysms and parent arteries with short‑term follow‑up.
           TNF-α synthesis, 3,6’dithiothalidomide (DTH). Both     Cardiovasc Pathol 2012;21:299‑306.
           groups showed a lower incidence of aneurysm formation   10.  Kosierkiewicz TA, Factor SM, Dickson DW. Immunocytochemical
           and rupture when compared with control mice.  The      studies of atherosclerotic lesions of cerebral berry aneurysms.
                                                     [62]
                                                                  J Neuropathol Exp Neurol 1994;53:399‑406.
           study also found that the inhibitor DTH led to an increase   11.  Starke  RM, Chalouhi  N, Ding  D, Raper  DM, Mckisic  MS,
           in aneurysm stabilization and consequently, a decrease   Owens GK, Hasan DM, Medel R, Dumont AS. Vascular smooth
                                           [62]
           in aneurysm rupture upon formation.  Although DTH      muscle cells in cerebral aneurysm pathogenesis. Transl Stroke Res
                                                                  2014;5:338‑46.
           is an inhibitor of TNF-α synthesis, the authors noted   12.  Nakajima N, Nagahiro S, Sano T, Satomi J, Satoh K. Phenotypic
           that the inhibitor’s actions are not fully understood as   modulation of smooth muscle cells in human cerebral aneurysmal
           other properties of the inhibitor may explain aneurysm   walls. Acta Neuropathol 2000;100:475‑80.
           stabilization and prevention of rupture. [62]      13.  Nixon AM, Gunel M, Sumpio BE. The critical role of hemodynamics
                                                                  in the development of cerebral vascular disease.  J  Neurosurg
                                                                  2010;112:1240‑53.
           CONCLUSION                                         14.  Nerem RM, Harrison DG, Taylor WR, Alexander RW. Hemodynamics
                                                                  and vascular endothelial biology.  J  Cardiovasc  Pharmacol
                                                                  1993;21 Suppl 1:S6‑10.
           Intensive investigation has implicated the inflammation   15.  Aoki T, Nishimura M, Matsuoka T, Yamamoto K, Furuyashiki T,
           in the complex pathophysiological processes that       Kataoka H, Kitaoka S, Ishibashi R, Ishibazawa A, Miyamoto S,
           underlie IA development, progression, and rupture.     Morishita  R, Ando  J, Hashimoto  N, Nozaki  K, Narumiya  S.
           Ongoing research shows how these inflammatory          PGE(2)  ‑EP(2) signalling in endothelium is activated by
           mechanisms can be clinically accessed and              haemodynamic stress and induces cerebral aneurysm through an
                                                                  amplifying loop via NF‑κB. Br J Pharmacol 2011;163:1237‑49.
           therapeutically modulated. Although advances in    16.  Hoh BL, Hosaka K, Downes DP, Nowicki KW, Wilmer EN, Velat GJ,
           microsurgical and endovascular management of IA        Scott EW. Stromal cell‑derived factor‑1 promoted angiogenesis
           will inevitably lead to lower procedural complication   and inflammatory cell infiltration in aneurysm walls. J Neurosurg
                                                                  2014;120:73‑86.
           rates, the need for a safe and effective noninvasive   17.  Ishibashi R, Aoki T, Nishimura M, Hashimoto N, Miyamoto S.
           therapeutic strategy to prevent aneurysmal SAH will    Contribution of mast cells to cerebral aneurysm formation. Curr
                                                                  Neurovasc Res 2010;7:113‑24.
           remain. Overall, these data suggest potential alternative   18.  Sadamasa  N, Nozaki  K, Hashimoto  N. Disruption of gene for
           medical treatment strategies for patients with human   inducible nitric oxide synthase reduces progression of cerebral
           cerebral aneurysms.                                    aneurysms. Stroke 2003;34:2980‑4.



          Neuroimmunol Neuroinflammation | Volume 2 | Issue 2 | April 15, 2015                              83
   86   87   88   89   90   91   92   93   94   95   96